Caveolin‐1 has been suggested as a possible therapeutic target for hypertension and atherosclerosis as its silencing prevents Angiotensin II (Ang II)‐induced pro‐atherogenic changes in both endothelial and smooth muscle cells, and Ang II‐induced pathological remodeling in mice (Forrester et al., 2017). Here, AGT is linked to atherosclerosis.